Association for Research in Vision and Ophthalmology

Based on data presented at ARVO 2023, Parikh discusses how anti-VEGF biosimilars may increase both patient and overall healthcare costs.

At ARVO 2023, Schmidt-Erfurth discusses new insights regarding disease activity in GA, observing reductions in both RPE and photoreceptor degeneration after intravitreal pegcetacoplan therapy in the OAKS and DERBY trials.

At ARVO 2023, Emanuelli discusses the primary analysis results of the phase 3 Pavilion trial evaluating the PDS with ranibizumab in patients with diabetic retinopathy without center-involved diabetic macular edema.

At ARVO 2023, Elizabeth Rossin, MD, PhD, elaborates on genetic and biological pathways that may contribute to epiretinal membrane risk.

A retrospective study of nearly 19,000 eyes presented at ARVO 2023 found patients with GA lost 2 lines of vision at year 3 and are at meaningful risk of nAMD.

At ARVO 2023, David Tabano, PhD, discussed the analysis of the largest real-world evaluation of treatment patterns and outcomes in DME patients treated with faricimab.

At ARVO 2023, 24-month data suggests the change from baseline in GA lesion growth consistently favored pegcetacoplan vs. sham across subgroups in DERBY and OAKS trials.

At ARVO 2023, Goldberg discusses how dual Ang-2/VEGF inhibition can provide greater vascular stability, which may contribute to faster fluid resolution and extended durability with faricimab treatment.

A personalized treat-and-extend–based regimen presented at ARVO 2023 suggested the long-term potential of faricimab to reduce the treatment burden for patients with DME.

An analysis of the TENAYA/LUCERNE presented at ARVO 2023 suggests faricimab more rapidly improved anatomic outcomes in patients with nAMD compared to aflibercept.

An analysis of the phase 2/3 PHOTON trial suggested the majority of patients with DME who received aflibercept 8 mg maintained 12- or 16-week dosing intervals.

A posthoc analysis of the phase 2 CANDELA study presented at ARVO 2023 suggests aflibercept 8 mg improved visual and anatomical outcomes compared with aflibercept 2 mg in eyes with nAMD.

At ARVO 2023, Do discusses the benefit of aflibercept 8 mg for DME in the phase 2/3 PHOTON trial, demonstrating non-inferiority in BCVA vs aflibercept 2 mg and no new safety concerns.

Presented at ARVO 2023, the nationwide data on nAMD real-world management in France suggest a discrepancy between avoiding the undertreatment of nAMD and the real-world management of the disease.

New research presented at ARVO 2023 suggests intravitreal brolucizumab led to the resolution of IRF and SRF in a significant number of patients with nAMD previously unresponsive to anti-VEGF therapy.

In an interview at ARVO 2023, Danzig discusses the post-hoc analysis from the GATHER trials, showing that a reduced rate of vision loss in patients receiving avacincaptad pegol was correlated with reduced GA growth.

At ARVO 2023, Caroline Baumal, MD, chief medical officer of Apellis Pharmaceuticals, discussed new phase 3 functional analyses of pegcetacoplan injection, the future of the GA treatment landscape, and the next unmet need in ophthalmology.

Phase 3 results presented at ARVO 2023 suggest a switch from aflibercept to SB15 led to no treatment-emergent issues such as loss of efficacy, increased adverse events, or increased immunogenicity.

An analysis of the STATUS program suggests the percentage of patients that received an annual eye exam increased from 65.2% to 72.8% in the clinics utilizing the IDx-DR system.

An analysis of the AlzEye study presented at ARVO 2023 suggests a deep-learning model showed promise in predicting three-year incident MACE using OCT.

As part of our ARVO 2023 coverage, Dr. Sheth sat down with Pravin Dugel, MD, President of Iveric Bio to discuss avacincaptad pegol for geographic atrophy and a look back at Dr. Dugel's career and his transition into industry.

In the first episode of this new game show, a team of ARVO 2022 investigators work to invent an innovative clinical trial.

From curative stem cell approaches to in-clinic subretinal injections, Arshad Khanani, MD, MA, navigates what the future drug class may entail.

An FDA decision could come as soon as this year. One expert stresses the need for improved screening, biomarker research, and patient communication beforehand.

Study author Arshad Khanani, MD, MA, discusses how the novel-targeting gene therapy candidate may uniquely benefit patients with treated retina disease.

Theodore Leng, MD, MS, discusses his team's IRIS registry findings suggesting a need for quantifying how vision-loss patients are impacted by functional or quality-of-life measures.

Data show half of all eyes with CRVO were still being treated at 36-months.

Treatment delay and steroid usage were both associated with worse improvements in long term BVA and CST in patients with RVO-related macular edema.

Veeral S. Sheth, MD, MBA, gives an update on his practice's adoption of the novel PDS in patients with AMD—and discusses other potential methods of anti-VEGF delivery.

These data further elucidate the relationship between mental health and diabetic retinopathy.